A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma

Phase 1

• Conditions: Patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma; MedDRA version: 14.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

• Registration Number: EUCTR2008-005870-11-GB
• Lead Sponsor: ovartis Pharma Services AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-03-15
• Study Completion: 2012-04-04
• Last Update Posted: 25 November 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients with histological confirmation of transitional cell carcinoma of the bladder,
urethra, ureter, or renal pelvis
• Locally advanced or metastatic disease
2. Archival tumor tissue available for Novartis designated FGFR3 mutational status analysis
3. Patients with documented progressive disease at baseline: progressive disease defined as
new or progressive lesions on cross-sectional imaging
4. Patients with at least one measurable site of disease as defined by RECIST criteria that has
not been previously irradiated
5. Previously treated with at least 1 but not more than 3 systemic cytotoxic regimens, with at
least one of these regimens including at least one of the following: cisplatin, carboplatin,
gemcitabine or taxane, administered in the perioperative or advanced setting and may have
been administered sequentially (e.g., first-line treatment followed by second-line treatment
at time of progression) or as part of a single regimen
6. Age = 18 years
7. WHO Performance Status = 2
8. Willing and able to take oral medication, comply with scheduled visits, treatment plan and
laboratory tests
9. Signed and witnessed informed consent form obtained prior to any screening procedures
10. Required baseline laboratory values:
• Absolute neutrophil count (ANC) = 1,500 cells/mm3 [SI units 1.5 x 109/L]
• Platelets = 100,000 cells/mm3 [SI units 100 x 109/L]
• Hemoglobin = 9.0 g/dL [SI units 90 g/L]
• AST/SGOT and ALT/SGPT = 3.0 x Upper Limit of Normal [ULN] (with or without metastases)
• Bilirubin = 1.5 x ULN
• Serum creatinine = 1.5 x ULN
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Patients with known brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases
2. Patients with history of another malignancy within the last three years prior to study entry, with the exception of adequately treated basal cell carcinoma , squamous cell carcinoma or non-melanomatous skin cancer, excised carcinoma in situ of the cervix, or adenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is non-detectable
3. Patients who have received the last administration of an anti-cancer therapy, including: chemotherapy, immunotherapy, hormonal therapy, and targeted therapy, but excluding: nitrosourea, mitomycin-C, monoclonal antibodies, and radiation = 14 days prior to starting study drug, or who have not recovered from side effects of such therapy
4. Patients who have received the last administration of nitrosourea or mitomycin-C = 6 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
5. Patients who received the last administration of an anti-cancer monoclonal antibody = 4 weeks prior to starting study drug, or who haven't recovered from the side effects of such therapy
6. Patients who have received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) = 4 weeks or limited field radiation for palliation = 2 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
7. Patients who have undergone major surgery = 2 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
8. Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:
a. Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
• History or presence of serious uncontrolled ventricular arrhythmias or presence of serious uncontrolled atrial fibrillation
• Clinically significant resting bradycardia
• LVEF, assessed by 2-D echocardiogram < 50% or lower limit of normal (whichever is higher) or multiple gated acquisition scan, < 45 % or lower limit of normal (whichever is higher)
• Any of the following within 6 months prior to study entry: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)
• Uncontrolled hypertension defined by a SBP = 160 mm Hg and/or DBP = 100 mm Hg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to study entry.
b. Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month
c. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of TKI258 (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
d. Known diagnosis of human immunodefi

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified